Dietressa (Dietressa)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsplozenges
Composition:

Active substances:

Antibodies to cannabinoid receptor type 1, affinity purified - 0.006 g. *

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* are applied to lactose in the form of a mixture of three active water-alcohol dilutions of the substance diluted 10012, 10030, 100200 time.

Description:

Tablets are flat-cylindrical, with a risk and chamfer, from white to almost white. On the flat side with the risk of inscription MATERIA MEDICA, on the other flat side there is an inscription DIETRESSA.

Pharmacotherapeutic group:Obesity medication
ATX: & nbsp
  • Other preparations for the treatment of obesity
    • Pharmacodynamics:

    Through the mechanisms of allosteric modulation, the drug sensitizes the cannabinoid type I receptor, which is accompanied by an increase in its sensitivity to endogenous cannabinoid neuropeptides. As a consequence, endocannabinoid regulation of the mesolimbic system, including the food center in the hypothalamus, is normalized.

    It has been experimentally shown that when the drug is injected into the animal, the self-stimulation of the lateral hypothalamus occurs, indicating a saturation of the system of positive emotional reinforcement, a decrease in the euphorigenic significance of food, a decrease in body weight gain in conditions of a high-fat diet.
    Admission of the drug is accompanied by a retarding effect on the processes of obesity: a reduction in food intake and weight loss, without causing both inhibitory and stimulating effects on higher nervous activity.

    The effect of weight loss is due not only to central, but also peripheral mechanisms - due to modulation of cannabinoid receptors of adipocytes (fat cells), activation of basic metabolism in them.

    The drug does not cause addiction, drug dependence, does not have an addictive effect.
    Pharmacokinetics:

    The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the preparation.

    Indications:

    Long-term therapy of patients with excessive body weight or obesity of I-II degree (body mass index ≥ 25 kg / m2) in combination with a moderately hypocaloric diet.

    Contraindications:

    Increased individual sensitivity to components preparation. Dietressa not recommended for use in children under the age of 18 in connection with the insufficiency of data by effectiveness and safety for this age.

    Pregnancy and lactation:

    Safety of Dietress application in pregnant women and during lactation has not been studied. If necessary, taking the drug should take into account the risk / benefit ratio.

    Dosing and Administration:

    Inside. Reception is recommended 6 tablets per day for 1-2 tablets (keep in your mouth until complete dissolution) 15-30 minutes before meals. It is desirable to combine treatment from moderately hypocaloric diet. Take long - up to three months. If necessary, the course can be resumed.


    Side effects:

    When using the drug for the indicated indications and in the indicated dosages, the side effect was not revealed. Possible reactions of increased individual sensitivity to the components of the drug.

    Overdose:

    There have been no cases of overdose to date. In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.

    Interaction:There have been no incidents of incompatibility with other drugs to date.
    Special instructions:

    The composition of the drug includes lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.

    In a small number of cases in the early course of therapy Dietressoy may be a temporary (two to eight days), a slight increase of appetite without causing weight gain and do not require discontinuation of therapy.
    Effect on the ability to drive transp. cf. and fur:Dietressa does not affect the ability to drive vehicles and other potentially dangerous machinery.
    Form release / dosage:Lozenges.
    Packaging:For 20 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil. For 1, 2 or 5 contour mesh packages together with the instruction for medical use are placed in a pack of cardboard.
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-006 933/10
    Date of registration:21.07.2010
    The owner of the registration certificate:NPF Materia Medica Holding, OOO NPF Materia Medica Holding, OOO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp07.02.16
    Illustrated instructions
      Instructions
      Up